CRISPR Therapeutics to focus on CASGEVY launch, multiple clinical trials.

CRISPR Therapeutics expects 2026 to be a data-rich year with multiple milestones across its portfolio. The launch of CASGEVY will continue to accelerate, potentially reaching multi-billion-dollar potential. The company has a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities. Its broad pipeline is supported by leading gene-editing and siRNA platforms across cardiovascular, autoimmune, oncology, and rare diseases.